Combination therapy of allergic rhinitis: efficacy, safety and impact on quality of life

Cover Page


Cite item

Full Text

Abstract

Currently, allergic rhinitis is one of the most common allergic diseases, and its significance is often underestimated by both doctors and patients, resulting in increased severity, decreased physical, professional, and social activity, sleep disturbance, and the impairment of the quality of life.

Despite modern drug availability, the control level over allergic rhinitis symptoms in routine clinical practice remains low. Patients who do not receive a quick result from using intranasal glucocorticosteroids, which have anti-inflammatory and pathogenetic properties, prefer fast-acting decongestants instead, which can lead to chronization and adverse events. The use of intranasal glucocorticosteroids and antihistamines combination, which have additive effects on the key pathogenesis stages of allergic inflammation, allows for rapid treatment of the most severe rhinitis symptoms and can improve adherence to therapy.

This review presents the results of clinical studies and key characteristics of the new nasal spray of the olopatadine and mometasone fixed combination, confirming the high efficacy and good safety profile of olopatadine + mometasone. The administration of olopatadine and mometasone fixed combination provides rapid relief from nasal and ocular symptoms in patients with allergic rhinitis, ultimately leading to an improvement in the quality of life.

Full Text

ADDITIONAL INFORMATION

Funding source.This study was supported by Glenmark.

Competing interests.The authors declare that they have no competing interests.

Author contribution. The contribution of all authors to the work is equal. All authors made a substantial contribution to the conception of the work, acquisition, analysis, interpretation of data for the work, drafting and revising the work, final approval of the version to be published and agree to be accountable for all aspects of the work.

 

Table 1. Stepwise approach for Allergic Rhinitis Management

 

Иммунотерапия (АСИТ)

Контроль факторов внешней среды (элиминационные мероприятия)

Фармакотерапия для контроля симптомов

1-я ступень

2-я ступень

3-я ступень

4-я ступень (лечение только специалистом)

Один из:

·                     нсН1-АГ

·                     интраназальные АГ

·                     кромоглициевая кислота (назальный препарат)

·                     АЛР

Один из:

·                     ИНГКС (предпочтительно)

·                     нсН1-АГ

·                     интраназальные АГ

·                     АЛР

Комбинация ИНГКС с одним или более из:

·                     нсН1-АГ

·                     интраназальные АГ

·                     АЛР

·                     Рассмотреть терапию тяжелого АР омализумабом

·                     Рассмотреть хирургическое лечение сопутствующей патологии

Препараты скорой помощи

Адреномиметики коротким курсом

Глюкокортикоиды (системного действия, пероральные)

Перепроверить диагноз и/или приверженность лечению либо влияние сопутствующих заболеваний и/или анатомических аномалий, прежде чем увеличивать терапию (step-up)

     

Note: nsH1-AH – non-sedative systemic H1 antihistamine (second generation); LTRA – leukotriene receptor antagonists; INCS – intranasal corticosteroids – corticosteroids for topical, nasal application (ATC code R01AD).

Table 2. Frequency of adverse events in Ryaltris ® studies

     Investigational drug 

 

Adverse event

Olopatadine+

mometasone

(N=789)

Olopatadine

(N=751)

Mometasone

(N=746)

Placebo

(N=776)

Dysgeusia

3.0%

2.1%

0.0%

0.3%

Epistaxis

1.0%

1.5%

0.8%

0.6%

Nasal discomfort

1.0%

0.3%

0.5%

0.8%

Figure 1. Visual analog scale AR

Figure 2. Mean change in scores from baseline to day 15 on the RQLQ(S) scale with Ryaltris® compared with placebo

×

About the authors

Ksenia S. Pavlova

National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia

Author for correspondence.
Email: ksenimedical@gmail.com
ORCID iD: 0000-0002-4164-4094
SPIN-code: 7593-0838
Scopus Author ID: 7004658159
ResearcherId: P-9255-2017

MD, Cand. Sci. (Med.)

Russian Federation, 24, Kashirskoe shosse, Moscow, 115522

Darya S. Kulichenko

National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia

Email: darya.mdinaradze@yandex.ru
ORCID iD: 0000-0002-7375-1759
SPIN-code: 2036-0430

младший научный сотрудник

Russian Federation, 24, Kashirskoe shosse, Moscow, 115522

Oksana M. Kurbacheva

National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia

Email: kurbacheva@gmail.com
ORCID iD: 0000-0003-3250-0694
SPIN-code: 5698-6436

MD, Dr. Sci. (Med.), Professor

Russian Federation, 24, Kashirskoe shosse, Moscow, 115522

References

  1. Federal clinical guidelines for the diagnosis and treatment of allergic rhinitis. Moscow: Russian Association of Allergists and Clinical Immunologists. National Medical Association of Otorhinolaryngologists. Union of Pediatricians of Russia; 2020. 114 p. (In Russ).
  2. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J. 2004;24(5):758–764. doi: 10.1183/09031936.04.00013904
  3. Bousquet PJ, Bachert C, Canonica GW, et al. Uncontrolled allergic rhinitis during treatment and its impact on quality of life: a cluster randomized trial. J Allergy Clin Immunol. 2010;126(3):666–668. doi: 10.1016/j.jaci.2010.06.034
  4. Asher MI, Montefort S, Björkstén B, et al.; ISAAC Phase Three Study Group. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733–743. doi: 10.1016/S0140-6736(06)69283-0
  5. Bousquet J, Schünemann HJ, Togias A, et al. Allergic Rhinitis and Its Impact on Asthma Working Group. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70–80.e3. doi: 10.1016/j.jaci.2019.06.049
  6. Novik AA. Guidelines for the study of quality of life in medicine. Saint-Petersburg: Neva; 2002. 315 р. (In Russ).
  7. Bousquet J, Khaltaev N, Cruz AA, et al. World Health Organization; GA(2)LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8–160. doi: 10.1111/j.1398-9995.2007.01620.x
  8. Juniper EF, Thompson AK, Roberts JN. Can the standard gamble and rating scale be used to measure quality of life in rinoconjunctivitis? Comparison with the RQLQ and SF-36. Allergy. 2002;57(3):201–206. doi: 10.1034/j.1398-9995.2002.1o3306.x
  9. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991;21(1):77–83. doi: 10.1111/j.1365-2222.1991.tb00807.x
  10. Blaiss MS. Cognitive, social, and economic costs of allergic rhinitis. Allergy Asthma Proc. 2000;21(1):7–13. doi: 10.2500/108854100778248953
  11. Cleland J.A., Mike T. and David B.P. Pharmacoeconomics of asthma treatment. Expert Opinion on Pharmacotherapy. 2003;4: 311–318. doi: 10.1517/14656566.4.3.311
  12. Juniper EF. Measuring health-related quality of life in rhinitis. J Allergy Clin Immunol. 1997;99(2):742–749. doi: 10.1016/s0091-6749(97)90000-2
  13. Juniper EF, Guyatt GH, Griffith LE, et al. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol. 1996;98(4):843–845. doi: 10.1016/s0091-6749(96)70135-5
  14. Thompson AK, Juniper E, Meltzer EO. Quality of life in patients with allergic rhinitis. Ann Allergy Asthma Immunol. 2000;85(5): 338–347. doi: 10.1016/S1081-1206(10)62543-4
  15. Uzzaman A, Metcalfe DD, Komarow HD. Acoustic rhinometry in the practice of allergy. Ann Allergy Asthma Immunol. 2006;97(6): 745−751. doi: 10.1016/S1081-1206(10)60964-7
  16. Jutel M, Agache I, Bonini S, et al. International consensus on allergy immunotherapy. J Allergy Clin Immunol. 2015;136(3): 556–568. doi: 10.1016/j.jaci.2015.04.047
  17. Bousquet J, Schünemann HJ, Hellings PW, et al.; MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. J Allergy Clin Immunol. 2016;138(2):367–374.e2. doi: 10.1016/j.jaci.2016.03.025
  18. Akdis C, Jutel M, Akdis M. Regulatory effects of histamine and histamine receptor expression in human allergic immune responses. Chem Immunol Allergy. 2008;94:67–82. doi: 10.1159/000154858
  19. Sher ER, Ross JA. Intranasal corticosteroids: the role of patient preference and satisfaction. Allergy Asthma Proc. 2014;35(1):24–33. doi: 10.2500/aap.2014.35.3725
  20. Al Sayyad JJ, Fedorowicz Z, Alhashimi D, et al. Topical nasal steroids for intermittent and persistent allergic rhinitis in children. Cochrane Database Syst Rev. 2007;2007(1):CD003163. doi: 10.1002/14651858.CD003163.pub4
  21. Penagos M, Compalati E, Tarantini F, et al. Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis. Meta-analysis of randomized, double-blind, placebo-controlled, clinical trials. Allergy. 2008;63(10):1280–1291. doi: 10.1111/j.1398-9995.2008.01808.x
  22. Rodrigo GJ, Neffen H. Efficacy of fluticasone furoate nasal spray vs. placebo for the treatment of ocular and nasal symptoms of allergic rhinitis: a systematic review. Clin Exp Allergy. 2011;41(2):160–170. doi: 10.1111/j.1365-2222.2010.03654.x
  23. Yáñez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2002;89(5):479–484. doi: 10.1016/S1081-1206(10)62085-6
  24. Bielory L, Chun Y, Bielory BP, et al. Impact of mometasone furoate nasal spray on individual ocular symptoms of allergic rhinitis: a meta-analysis. Allergy. 2011;66(5):686–693. doi: 10.1111/j.1398-9995.2010.02543.x
  25. Watson WT, Becker AB, Simons FE. Treatment of allergic rhinitis with intranasal corticosteroids in patients with mild asthma: effect on lower airway responsiveness. J Allergy Clin Immunol. 1993;91(1 Pt 1): 97–101. doi: 10.1016/0091-6749(93)90301-u
  26. Debbaneh PM, Bareiss AK, Wise SK, et al. Intranasal azelastine and fluticasone as combination therapy for allergic rhinitis: systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2019;161(3):412–418. doi: 10.1177/0194599819841883
  27. Roberts G, Pfaar O, Akdis CA, et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy. 2018;73(4): 765–798. doi: 10.1111/all.13317
  28. Meltzer EO, Farrar JR, Sennett C. Findings from an online survey assessing the burden and management of seasonal allergic rhinoconjunctivitis in US Patients. J Allergy Clin Immunol Pract. 2017;5(3):779–789.e6. doi: 10.1016/j.jaip.2016.10.010
  29. Valovirta E, Myrseth SE, Palkonen S. The voice of the patients: allergic rhinitis is not a trivial disease. Curr Opin Allergy Clin Immunol. 2008;8(1):1–9. doi: 10.1097/ACI.0b013e3282f3f42f
  30. Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2017 revision. J Allergy Clin Immunol. 2017;140(4):950–958. doi: 10/1016/j/jaci.2017.03.050
  31. Meltzer EO, Wallace D, Dykewicz M, et al. Minimal clinically important difference (mcid) in allergic rhinitis: agency for healthcare research and quality or anchor-based thresholds? J Allergy Clin Immunol Pract. 2016;4(4):682–688.e6. doi: 10.1016/j.jaip.2016.02.006
  32. Tohidinik HR, Mallah N, Takkouche B. History of allergic rhinitis and risk of asthma; a systematic review and meta-analysis. World Allergy Organ J. 2019;12(10):100069. doi: 10.1016/j.waojou.2019.100069
  33. Segall N, Prenner B, Lumry W, et al. Long-term safety and efficacy of olopatadine-mometasone combination nasal spray in patients with perennial allergic rhinitis. Allergy Asthma Proc. 2019;40(5):301–310. doi: 10.2500/aap.2019.40.4233
  34. Patel P, Salapatek AM, Tantry SK. Effect of olopatadine-mometasone combination nasal spray on seasonal allergic rhinitis symptoms in an environmental exposure chamber study. Ann Allergy Asthma Immunol. 2019;122(2):160–166.e1. doi: 10.1016/j.anai.2018.10.011
  35. Patel P, Salapatek AM, Talluri RS, et al. Pharmacokinetics of intranasal mometasone in the fixed-dose combination GSP301 versus two monotherapy intranasal mometasone formulations. Allergy Asthma Proc. 2018;39(3):232–239. doi: 10.2500/aap.2018.39.4134
  36. Andrews CP, Mohar D, Salhi Y, et al. Efficacy and safety of twice-daily and once-daily olopatadine-mometasone combination nasal spray for seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2020;124(2):171–178.e2. doi: 10.1016/j.anai.2019.11.007
  37. Hampel FC, Pedinoff AJ, Jacobs RL, et al. Olopatadine-mometasone combination nasal spray: Evaluation of efficacy and safety in patients with seasonal allergic rhinitis. Allergy Asthma Proc. 2019;40(4):261–272. doi: 10.2500/aap.2019.40.4223
  38. Gross GN, Berman G, Amar NJ, et al. Efficacy and safety of olopatadine-mometasone combination nasal spray for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2019; 122(6):630–638.e3. doi: 10.1016/j.anai.2019.03.017

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Visual analog scale allergic rhinitis.

Download (611KB)
Indexing metadata
3. Fig. 2. Mean change in scores from baseline to day 15 on the RQLQ(s) scale with combined (olopatadine + mometasone) nasal spray compared with placebo.

Download (396KB)
Indexing metadata

Copyright © Pharmarus Print Media, 2022



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies